Sivelestat-Loaded Neutrophil-Membrane-Coated Antioxidative Nanoparticles for Targeted Endothelial Protection in Sepsis
<b>Background/Objectives</b>: This study aims to develop and evaluate neutrophil-membrane-coated nanoparticles (Siv@NMs) encapsulating sivelestat for the treatment of sepsis-induced endothelial injury. Leveraging the intrinsic chemotactic properties of neutrophil membranes, Siv@NMs are e...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/17/6/766 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849705606281166848 |
|---|---|
| author | Juexian Wei Aijia Zhong Yuting Zhang Ehua Deng Hengzong Mo Hongyu Zhao Jiayu Huang Huaidong Peng Kaiyin Zhang Xiaohui Chen Haifeng Mao Yixin Chen Yongcheng Zhu |
| author_facet | Juexian Wei Aijia Zhong Yuting Zhang Ehua Deng Hengzong Mo Hongyu Zhao Jiayu Huang Huaidong Peng Kaiyin Zhang Xiaohui Chen Haifeng Mao Yixin Chen Yongcheng Zhu |
| author_sort | Juexian Wei |
| collection | DOAJ |
| description | <b>Background/Objectives</b>: This study aims to develop and evaluate neutrophil-membrane-coated nanoparticles (Siv@NMs) encapsulating sivelestat for the treatment of sepsis-induced endothelial injury. Leveraging the intrinsic chemotactic properties of neutrophil membranes, Siv@NMs are engineered to achieve site-specific delivery of sivelestat to damaged endothelia, thereby overcoming the limitations of conventional therapies in mitigating endothelial dysfunction and multiorgan failure associated with sepsis. <b>Methods</b>: Siv@NMs were synthesized through a combination of ultrasonication and extrusion techniques to encapsulate sivelestat within neutrophil-membrane-derived vesicles. Comprehensive physicochemical characterization included analysis of particle size distribution, zeta potential, and encapsulation efficiency. Stability profiles and controlled release kinetics were systematically evaluated under simulated conditions. In vitro investigations encompassed (1) endothelial cell biocompatibility assessment via cytotoxicity assays, (2) investigation of the targeting efficiency in suppressing endothelial neutrophil extracellular trap generation during inflammation, and (3) ROS-scavenging capacity quantification using flow cytometry with DCFH-DA fluorescent probes. In vivo therapeutic efficacy was validated using a cecal ligation and puncture (CLP) sepsis mouse model, with multiparametric monitoring of endothelial function, inflammatory markers, ROS levels, and survival outcomes. <b>Results</b>: The optimized Siv@NMs exhibited an average particle size of approximately 150 nm, and a zeta potential of −10 mV was achieved. Cellular studies revealed that (1) Siv@NMs selectively bound to inflammatory endothelial cells with minimal cytotoxicity, and (2) Siv@NMs significantly reduced ROS accumulation in endothelial cells subjected to septic stimuli. In vitro experiments demonstrated that Siv@NMs treatment markedly attenuated endothelial injury biomarkers’ expression (ICAM-1 and iNOS), suppressed formation of neutrophil extracellular traps, and improved survival rates compared to treatment with free sivelestat. <b>Conclusions</b>: The neutrophil-membrane-coated nanoparticles loaded with sivelestat present a breakthrough strategy for precision therapy of sepsis-associated endothelial injury. This bioengineered system synergistically combines targeted drug delivery with multimodal therapeutic effects, including ROS mitigation, anti-inflammatory action, and endothelial protection. These findings substantiate the clinical translation potential of Siv@NMs as a next-generation nanotherapeutic for sepsis management. |
| format | Article |
| id | doaj-art-78f79c95c54244209a11b0baec4c5e86 |
| institution | DOAJ |
| issn | 1999-4923 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj-art-78f79c95c54244209a11b0baec4c5e862025-08-20T03:16:25ZengMDPI AGPharmaceutics1999-49232025-06-0117676610.3390/pharmaceutics17060766Sivelestat-Loaded Neutrophil-Membrane-Coated Antioxidative Nanoparticles for Targeted Endothelial Protection in SepsisJuexian Wei0Aijia Zhong1Yuting Zhang2Ehua Deng3Hengzong Mo4Hongyu Zhao5Jiayu Huang6Huaidong Peng7Kaiyin Zhang8Xiaohui Chen9Haifeng Mao10Yixin Chen11Yongcheng Zhu12Department of Emergency, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, ChinaSchool of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, ChinaDepartment of Physiology, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 511436, ChinaSchool of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, ChinaDepartment of Clinical Medicine, The Second Clinical Medicine School of Guangzhou Medical University, Guangzhou 510260, ChinaDepartment of Emergency, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, ChinaDepartment of Emergency, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, ChinaDepartment of Pharmacy, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, ChinaDepartment of Emergency, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, ChinaDepartment of Emergency, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, ChinaDepartment of Emergency, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, ChinaDepartment of Emergency, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, ChinaDepartment of Emergency, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, China<b>Background/Objectives</b>: This study aims to develop and evaluate neutrophil-membrane-coated nanoparticles (Siv@NMs) encapsulating sivelestat for the treatment of sepsis-induced endothelial injury. Leveraging the intrinsic chemotactic properties of neutrophil membranes, Siv@NMs are engineered to achieve site-specific delivery of sivelestat to damaged endothelia, thereby overcoming the limitations of conventional therapies in mitigating endothelial dysfunction and multiorgan failure associated with sepsis. <b>Methods</b>: Siv@NMs were synthesized through a combination of ultrasonication and extrusion techniques to encapsulate sivelestat within neutrophil-membrane-derived vesicles. Comprehensive physicochemical characterization included analysis of particle size distribution, zeta potential, and encapsulation efficiency. Stability profiles and controlled release kinetics were systematically evaluated under simulated conditions. In vitro investigations encompassed (1) endothelial cell biocompatibility assessment via cytotoxicity assays, (2) investigation of the targeting efficiency in suppressing endothelial neutrophil extracellular trap generation during inflammation, and (3) ROS-scavenging capacity quantification using flow cytometry with DCFH-DA fluorescent probes. In vivo therapeutic efficacy was validated using a cecal ligation and puncture (CLP) sepsis mouse model, with multiparametric monitoring of endothelial function, inflammatory markers, ROS levels, and survival outcomes. <b>Results</b>: The optimized Siv@NMs exhibited an average particle size of approximately 150 nm, and a zeta potential of −10 mV was achieved. Cellular studies revealed that (1) Siv@NMs selectively bound to inflammatory endothelial cells with minimal cytotoxicity, and (2) Siv@NMs significantly reduced ROS accumulation in endothelial cells subjected to septic stimuli. In vitro experiments demonstrated that Siv@NMs treatment markedly attenuated endothelial injury biomarkers’ expression (ICAM-1 and iNOS), suppressed formation of neutrophil extracellular traps, and improved survival rates compared to treatment with free sivelestat. <b>Conclusions</b>: The neutrophil-membrane-coated nanoparticles loaded with sivelestat present a breakthrough strategy for precision therapy of sepsis-associated endothelial injury. This bioengineered system synergistically combines targeted drug delivery with multimodal therapeutic effects, including ROS mitigation, anti-inflammatory action, and endothelial protection. These findings substantiate the clinical translation potential of Siv@NMs as a next-generation nanotherapeutic for sepsis management.https://www.mdpi.com/1999-4923/17/6/766neutrophil-membrane-coated nanoparticlessivelestatendothelial injurysepsisROS scavengingdrug delivery system |
| spellingShingle | Juexian Wei Aijia Zhong Yuting Zhang Ehua Deng Hengzong Mo Hongyu Zhao Jiayu Huang Huaidong Peng Kaiyin Zhang Xiaohui Chen Haifeng Mao Yixin Chen Yongcheng Zhu Sivelestat-Loaded Neutrophil-Membrane-Coated Antioxidative Nanoparticles for Targeted Endothelial Protection in Sepsis Pharmaceutics neutrophil-membrane-coated nanoparticles sivelestat endothelial injury sepsis ROS scavenging drug delivery system |
| title | Sivelestat-Loaded Neutrophil-Membrane-Coated Antioxidative Nanoparticles for Targeted Endothelial Protection in Sepsis |
| title_full | Sivelestat-Loaded Neutrophil-Membrane-Coated Antioxidative Nanoparticles for Targeted Endothelial Protection in Sepsis |
| title_fullStr | Sivelestat-Loaded Neutrophil-Membrane-Coated Antioxidative Nanoparticles for Targeted Endothelial Protection in Sepsis |
| title_full_unstemmed | Sivelestat-Loaded Neutrophil-Membrane-Coated Antioxidative Nanoparticles for Targeted Endothelial Protection in Sepsis |
| title_short | Sivelestat-Loaded Neutrophil-Membrane-Coated Antioxidative Nanoparticles for Targeted Endothelial Protection in Sepsis |
| title_sort | sivelestat loaded neutrophil membrane coated antioxidative nanoparticles for targeted endothelial protection in sepsis |
| topic | neutrophil-membrane-coated nanoparticles sivelestat endothelial injury sepsis ROS scavenging drug delivery system |
| url | https://www.mdpi.com/1999-4923/17/6/766 |
| work_keys_str_mv | AT juexianwei sivelestatloadedneutrophilmembranecoatedantioxidativenanoparticlesfortargetedendothelialprotectioninsepsis AT aijiazhong sivelestatloadedneutrophilmembranecoatedantioxidativenanoparticlesfortargetedendothelialprotectioninsepsis AT yutingzhang sivelestatloadedneutrophilmembranecoatedantioxidativenanoparticlesfortargetedendothelialprotectioninsepsis AT ehuadeng sivelestatloadedneutrophilmembranecoatedantioxidativenanoparticlesfortargetedendothelialprotectioninsepsis AT hengzongmo sivelestatloadedneutrophilmembranecoatedantioxidativenanoparticlesfortargetedendothelialprotectioninsepsis AT hongyuzhao sivelestatloadedneutrophilmembranecoatedantioxidativenanoparticlesfortargetedendothelialprotectioninsepsis AT jiayuhuang sivelestatloadedneutrophilmembranecoatedantioxidativenanoparticlesfortargetedendothelialprotectioninsepsis AT huaidongpeng sivelestatloadedneutrophilmembranecoatedantioxidativenanoparticlesfortargetedendothelialprotectioninsepsis AT kaiyinzhang sivelestatloadedneutrophilmembranecoatedantioxidativenanoparticlesfortargetedendothelialprotectioninsepsis AT xiaohuichen sivelestatloadedneutrophilmembranecoatedantioxidativenanoparticlesfortargetedendothelialprotectioninsepsis AT haifengmao sivelestatloadedneutrophilmembranecoatedantioxidativenanoparticlesfortargetedendothelialprotectioninsepsis AT yixinchen sivelestatloadedneutrophilmembranecoatedantioxidativenanoparticlesfortargetedendothelialprotectioninsepsis AT yongchengzhu sivelestatloadedneutrophilmembranecoatedantioxidativenanoparticlesfortargetedendothelialprotectioninsepsis |